INJECTABLE PRESENTATIONS, SYRINGES AND EXTENDED-RELEASE AND / OR CONTROLLED-RELEASE LANREOTIDE COMPOSITIONS
A less viscous lanreotide formulation in pre-filled syringes with finer needles addresses the challenge of high injection forces in Somatuline®, facilitating easier and less painful administration with sustained and controlled release profiles.
Patent Information
- Application Number
- FR2018052662
- Authority / Receiving Office
- FR · FR
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2018-03-28
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2038-03-28
AI Technical Summary
Current formulations of lanreotide, such as Somatuline®, require high injection forces due to their high viscosity, making manual administration difficult and painful, especially with standard syringes and needles, and they often necessitate specialized techniques and equipment for injection.
A pharmaceutical composition with reduced viscosity, containing lanreotide at concentrations between 18% to 25% and ethanol at 3% to 23% by weight, is formulated for use in pre-filled syringes with needles of 1.00 mm internal diameter or less, allowing for easier and less painful administration.
The new formulation significantly reduces the injection force required, enabling self-administration with standard syringes and finer needles, providing sustained and controlled release profiles with reduced burst and increased circulating levels of lanreotide, improving patient comfort and treatment efficacy.
Smart Images

Figure 00000036_0000 
Figure 00000037_0000 
Figure 00000038_0000
Abstract
Description
Advantageously, lanreotide is present at a concentration of 18%, 18.5%, 19%, 19.5%, 20%, 20.5% or 21% by weight relative to the total weight of the composition. If an injectable semi-solid is defined as a composition that, after injection, forms a manageable solid extrudate, the pharmaceutical composition, whether in its pure form or in a pre-filled syringe according to the present invention, is a viscous, but not semi-solid, composition. This composition can be injected using a standard injection device such as a manually operated syringe with a plunger rod, equipped with a conventional needle. The preferred dimensions of the syringe and needle are indicated above. Viscosity and other physical characteristics of compositions can be assessed as injectability when evaluating the administration step. Injectability can be determined by performing simulated injection tests and using various physical methods.10 Injectability can be reported as injection force or syringe injection force (SIF). The term "injectability", which can be determined by measuring the force of injection, refers to the suitability of the composition for parenteral administration using an injection device, such as a syringe or injector. The SIF can be determined using a dynamometer (L1000R, Lloyd Instruments Ltd.) equipped with a calibrated cell (NLC 100N, Lloyd Instruments Ltd.). The pharmaceutical composition according to the present invention can be packaged in a syringe with a diameter greater than 3.00 mm, preferably greater than or equal to 3.50 mm, coupled to a 20 mm long needle with an internal diameter ranging from 0.60 to 1.00 mm, and is tested for its suitability for injection during a simulated discharge at a speed of 100 mm / min, where the force applied by the instrument to the plunger and its displacement are recorded. The simulated injection is performed vertically in air. The maximum injection force, expressed in newtons (N), is derived from the data collected during the discharge. Such examples of injection forces are detailed in Example 10. It is known to those skilled in the art that with such thinner needles it is not possible to perform manual injections of commercial products of the Somatuline® type even with thin Somatuline® type syringes, and therefore even less so with standard syringes of larger internal diameter. According to a preferred embodiment, the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention exhibits an injectability 30 defined by an SIF ranging from 5 to 14 N when tested with the method defined above and a needle of 1.00 mm internal diameter for a composition containing 18% to 21% lanreotide. Preferably, the SIF of the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention is from 5 to 6 N. According to another preferred embodiment, the pharmaceutical composition, whether as such or in a pre-filled syringe according to the present invention, exhibits an injectability defined by a SIF ranging from 7 to 12 N when tested with the method defined above and a needle with an internal diameter of 0.80 mm for a composition containing 18% to 21% lanreotide. Preferably, the SIF of the pharmaceutical composition, whether as such or in a pre-filled syringe according to the present invention, ranges from 7 to 9 N. According to a preferred embodiment, the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention exhibits an injectability defined by an SIF ranging from 9 to 14 N when tested with the method defined above and a 0.6 mm internal diameter needle for a composition containing 18% to 21% lanreotide. Preferably, the SIF of the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention is from 9 to 12 N. By comparison, a commercial 25% lanreotide formulation cannot be manually extruded from a device with a syringe larger than 3.50 mm in diameter. Injecting such a formulation requires a 3.50 mm diameter syringe coupled with a 20 mm long needle with a 1.00 mm internal diameter, and applying a force greater than 14 N. The injection force measured in newtons with a device compatible with the commercial device 20 under the same conditions in all cases, goes for example from 14.3N with a composition of 24.6% representative of the commercial Somatuline® form to 5.5N for a composition of 19% lanreotide in water. Given that there is a residual force of the order of 2N linked to the friction of the device during vacuum injection, this is a reduction of more than 70% of the force required to inject these 2 compositions which are nevertheless similar, which demonstrates this useful threshold of exploitable property according to the invention. In terms of implantation force, the decrease in needle diameter results in a reduction that can make a decisive difference between a needle that is easily implanted, including by the patient himself, and a complicated implantation procedure that requires the experience, technique, and practice of a specialist. The implantation forces of the needles are proportional to their gauges. A seemingly small difference in diameter, such as between 1.00 mm and 1.20 mm, corresponds to an impact area or cross-section 1.5 times larger. The importance of reducing the diameter of the injection needle as much as possible to avoid pain and facilitate injection is illustrated in the article "Fracture mechanics model of needle cutting tissue" by Barnett et al. (2015), in which the authors demonstrate that there is a threshold force for penetration or insertion of needles through the skin: For needles with an external diameter ranging from 1.60 mm (16G) to 1.20 mm (18G), the forces are comparable and vary between 2.5 and 3 N, which could be considered high by a person skilled in the art; For needles with an external diameter ranging from 0.80 mm (21G) to 0.50 mm (25G), the forces are reduced by two, and vary between 1 and 1.5 N. 10 In fact, these seemingly small differences in diameter correspond to a loss of charge and therefore to an increase in the injection force which for the same product may make manual administration impossible. Another limitation of the needles used in current commercial presentations such as Somatuline® is related to the need to use thin-walled cannulas, for example, 0.10 mm, to avoid increasing the external diameter. This reduces the possibilities of having a long, sharp bevel and thus increases the risk of deformation and coring during implantation. All these effects can complicate and make the insertion of the needle into the tissues more painful. One of the advantages of the invention is therefore also the ability to return to cannulas with thicker walls, for example, between 0.10 and 0.20 mm, preferably 0.15 mm. Indeed, the bevel of a needle determines how the incision will be made, allowing the cannula to penetrate and inject the product. On a needle with an external diameter greater than 1.00 mm, thicker walls are preferable, offering more freedom in the bevel design. With thin walls, it is difficult to freely shape the needle tip, which can complicate the incision and make it painful for the patient. By using standard needles (1.00 mm and less external diameter) according to the invention, it is possible to modify the bevel to order, and therefore improve user comfort for a needle with an external diameter that remains smaller than that of the needles in current commercial compositions. 30 Finally, a needle with an external diameter of 1.00 mm or less implies less force of penetration and can therefore include a bevel made on a wall thickness of only 0.10 mm, thus reducing its external diameter relative to the internal diameter. Conversely, a needle with an external diameter of 1.20 mm or more implies more penetration force and would require a bevel made on a thickness of 0.15 mm, further increasing its external diameter relative to the internal diameter. A lanreotide composition of up to 21% can be loaded conventionally before plunger insertion, for example, with butyl in a 1 mL BD Hypak™ Long syringe sealed with a Luer-lock cap. Injections can be performed by attaching a standard 21G needle, either 25 mm or 16 mm, to the Luer-lock tip to obtain the same profiles at different injection and depth conditions, regardless of the deposition conditions. According to another aspect of the invention, the pharmaceutical composition itself, or 10, present in a pre-filled syringe, further comprises an alcohol, preferably ethanol. A person skilled in the art could have foreseen that the addition of organic solvents, even in low concentrations of approximately 5 to 10% by weight in water, would have led to stability problems. The inventors discovered that it is possible in presentations according to the invention to use this type of mixture with ethanol at a concentration of at least 5% and up to 25% in water which makes it possible to obtain stable and homogeneous lanreotide compositions. With low percentages of alcohol that do not cause pain on injection or local tolerance, the inventors discovered that these compositions are more viscous than those obtained with water alone at the same concentration of lanreotide, perhaps explaining the stability of the active ingredient under these conditions. 20 Pharmaceutical compositions as such or present in a pre-filled syringe Filled according to the present invention, comprising 3 to 23% and preferably 3 to 10% ethanol, these solutions allow for easier use and validation of processes for ready-to-use aseptic preparations, without the need for gamma irradiation in terminal sterilization. They also make it possible to consider solid presentations of lanreotide that are stable at room temperature, with simple and rapid extemporaneous preparations of the product to be injected. According to another preferred embodiment, the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention, comprises ethanol at a concentration of 3 to 23% by weight relative to the total weight of the composition, preferably 3 to 10% by weight relative to the total weight of the composition. According to another preferred embodiment, the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention containing lanreotide at 20% by weight, ethanol at a concentration of 5 to 25% by weight in water, exhibits a Injectability is defined by an SIF ranging from 7 to 9 N when tested with the method defined above. Preferably, the SIF of the pharmaceutical composition is from 7 to 8 N. For example, the injection force test performed with pharmaceutical compositions containing 20% by weight lanreotide, and 5% or 10% ethanol in water, shows forces of 8.3 N and 7.3 N respectively. These forces are nearly 50% lower than that of a representative 25% mixture of the commercial product. Considering that a manual injection force of around 15 N represents an acceptable maximum under the test conditions, any force reduction proposed by a presentation according to the invention that deviates sufficiently from this maximum constitutes a significant improvement. With these new water-ethanol mixture compositions, it is also possible to prepare higher concentrations of lanreotide, for example, close to 25%, comparable to commercial products, and to use a larger proportion of ethanol, but still in a small quantity to ensure safe injection, for example, 25% or less in water. This results in a composition that is much more fluid than current products (see Example 9). According to the injection shape test, such a composition can be injected, for example, with a needle of 0.80 mm internal diameter with a force of 7.3 N, which is 70% lower than that of a representative mixture of the 25% lanreotide commercial product. 20 The invention therefore also relates to a pharmaceutical composition as such or presented in a pre-filled syringe according to the present invention containing lanreotide at a concentration of about 18% to 25% and ethanol at a concentration of 3 to 23% by weight, these percentages being expressed in relation to the total weight of the composition. The results obtained in animals and presented in the examples indicate that the water-ethanol compositions of the present invention, compared to commercial formulations, allow for new lanreotide release profiles, and thus also make it possible, for example, to reduce the burst or Cmax by 1.5 to 2 times compared to the commercial product, which also allows for at least a 2x increase in circulating lanreotide levels 2 to 4 weeks after injection. (See Figures 2-4) 30 Preferably the compositions, kits or pre-filled syringes according to the invention which do not include those that do not contain ethanol, contain 18 to 21% lanreotide, and those containing ethanol contain 18 to 25% lanreotide. According to another embodiment, the compositions of the invention comprise at least one amino acid, preferably arginine, present at a concentration ranging from 0.1 to 13% by weight relative to the total weight of the composition. It has been shown that depending on the proportions and mixing conditions (type of medium, temperature and time) of lanreotide with at least one amino acid, it is possible to obtain a lanreotide release profile that is better controlled than that of current products such as Somatuline®, and with a duration of action from one week to several months. This approach, involving the addition of an amino acid, can lead to various new compositions. For example, arginine can be added to compositions containing different concentrations of lanreotide, for instance, at a concentration equal to or less than 21% in water. The amount by weight of arginine may vary between 0.1 and 13% relative to the total weight of the composition. According to another preferred embodiment, the pharmaceutical composition as such or in a pre-filled syringe according to the present invention is intended for prolonged release of lanreotide for at least 1 month and comprises or essentially consists of: -18%, 18.5%, 19%, 19.5%, 20%, 20.5% or 21% by weight of lanreotide; - from 0 to 23% by weight of ethanol, preferably from 3% to 10% by weight; - 0 to 13% by weight of arginine, preferably 1% to 13% by weight, even more than 20% preferably 2% to 13% by weight. It is also possible to adapt the release profile according to needs, starting from the same composition, by choosing the subcutaneous (SC) or intramuscular (IM) route of administration. All of these advantageous and novel features also constitute other objects of the invention. All these diluted forms combined with finer needles do not produce controlled volume deposits for in situ gelation but lead to greater diffusion or distribution at the injection point or to deposits with a flatter shape. One might have expected under these conditions to obtain rapid or uncontrolled releases, for example by solubilization of lanreotide, but unexpectedly, this 30 increase in the exchange surface leads to the formation of a smaller volume precipitate which controls the release differently and in a useful and reproducible way to solve the different problems described previously according to more conventional injections. A pharmaceutical composition as such or present in a pre-filled syringe according to the present invention is administered parenterally. According to a preferred embodiment, the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention is administered by subcutaneous, intramuscular or deep subcutaneous injection, and more preferably by subcutaneous injection. The inventors have discovered, among other things, a new formulation that allows for a more diluted version with a maximum of 21% lanreotide. When injected subcutaneously, this formulation provides more stable levels with a higher final concentration (Cmin) than current formulations, whether administered every 2 or 4 weeks. This type of profile is useful, for example, in acromegaly and is also likely to resolve issues of reduced efficacy towards the end of the 10-week interval between injections. The same formulation, when injected intramuscularly, will also achieve higher levels and Cmins than current formulations, with a profile that allows for individual patient needs to be tailored to the specific time between injections, even for periods shorter than 2 weeks when higher doses are required, as is useful, for example, in neuroendocrine tumors (NETs).These new presentations are also very advantageous for locoregional applications of lanreotide, such as in ophthalmology, diabetology, or dermatology. All these new formulations are easier to inject and certainly less painful than current products, both because of the finer needle used for injection and because the deposit is less compact or resistant, and therefore flatter. They are thus compatible with even 20 closely spaced injections. As mentioned previously, the injection force can then be, for example, more than three times lower than with commercial products, which facilitates, or even makes possible, administration by the patient themselves or by someone around them using a standard syringe-type hand device. A pharmaceutical composition as such or present in a pre-filled syringe according to the present invention is administered parenterally. According to a preferred embodiment, the pharmaceutical composition as such or in a pre-filled syringe according to the present invention is administered by subcutaneous, intramuscular, or deep subcutaneous injection, and more preferably by subcutaneous or deep subcutaneous injection. For the subcutaneous route, and in particular the deep subcutaneous route, which remains preferred, the injection volume is preferably not greater than 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, or 1 mL of a lanreotide composition at a concentration of 18 to 21% by weight of the composition. According to a preferred embodiment, the prolonged release of lanreotide is at least 2 months in humans. According to a preferred embodiment, the prolonged release of lanreotide is at least 3 months in humans. The pharmaceutical composition as such or present in a pre-filled syringe according to the present invention allows prolonged release for at least 7 days, 7 to 14 days, 14 to 28 days, 2 months i.e. 60 days or more than 2 months i.e. 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 or 90 days. According to a preferred embodiment, the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention allows for prolonged release for at least 60 days. 10 According to another preferred embodiment, the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention allows prolonged release for at least 7 days. According to another preferred embodiment, the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention allows for prolonged release for at least 90 days. According to a more preferred embodiment, the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention allows for prolonged release for at least 14 days. According to another, more preferred embodiment, the pharmaceutical composition in 20 as such or present in a pre-filled syringe according to the present invention allows for prolonged release for at least 28 days. As previously mentioned, lanreotide is a marketed analogue of somatostatin. It is indicated for the treatment of acromegaly due to growth hormone-secreting pituitary and non-pituitary tumors, for the management of symptoms and antiproliferative therapy of neuroendocrine tumors, particularly carcinoid tumors and VIPomas, and for the treatment of thyrotrophic adenoma. A pharmaceutical composition as such or present in a pre-filled syringe according to the present invention can therefore be useful in the treatment of acromegaly due to pituitary and non-pituitary tumors secreting a growth hormone, in the management of symptoms caused by neuroendocrine tumors as well as its control, in particular carcinoid tumors and VIPomas or for the treatment of thyrotropic adenoma. According to a preferred embodiment, a pharmaceutical composition as such or present in a pre-filled syringe according to the present invention is useful in the treatment of acromegaly or neuroendocrine tumors, for example, functional and non-functional gastroenteropancreatic neuroendocrine tumors. According to the modalities of the invention, a patient suffering from acromegaly or NETs can be treated by administration of a therapeutically active amount of the pharmaceutical composition described in any of the embodiments described below. According to one embodiment, the pharmaceutical composition as such or in a pre-filled syringe according to the present invention is administered or injected, or prepared for administration or injection, into a patient in need, no more frequently than every 2 weeks or preferably every 4, 8, 12, or 16 weeks. Preferably, it is administered or injected every 4 weeks. According to another preferred embodiment, the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention is administered or prepared for administration in a single injection. Preferably, the method comprises administering the pharmaceutical composition, either as such or in a pre-filled syringe according to the present invention, at least once every 2, 4, 8, 12, 14, or 16 weeks. More preferably, the method comprises administering the pharmaceutical composition, either as such or in a pre-filled syringe according to the present invention, at least once every 12 weeks. 20 According to another embodiment, the pharmaceutical composition as such or The pharmaceutical composition, presented in a pre-filled syringe according to the present invention, is administered by a single injection. Preferably, the pharmaceutical composition itself, or as presented in a pre-filled syringe according to the present invention, is injected intramuscularly, subcutaneously, or deep subcutaneously. According to another embodiment, the pharmaceutical composition itself, or presented in a pre-filled syringe according to the present invention, is administered at a dose of 60, 90, 120, 240, or 360 mg of lanreotide. Preferably, the pharmaceutical composition itself, or presented in a pre-filled syringe according to the present invention, is administered at a dose of 120, 240, or 360 mg of lanreotide. The advantages of this invention, which allow for easier injections with finer needles and smaller, less noticeable, and therefore more comfortable, in-situ deposition, make it possible to prepare these larger doses for a single injection, such as double or more the doses of commercial products, doses which correspond to a treatment need, for example, for neuroendocrine tumors. According to the invention, a patient suffering from a neuroendocrine tumor can be treated by administering a therapeutically active amount of the pharmaceutical composition described in any one of the above embodiments. Preferably, the pharmaceutical composition itself, or in a pre-filled syringe according to the present invention, is administered for the antiproliferative control of neuroendocrine tumors, or to prevent the symptoms caused by these neuroendocrine tumors. According to one embodiment, these symptoms are selected from hot flashes, diarrhea and abdominal cramps. According to the modalities of the invention, a patient suffering from thyrotrophic adenoma can be treated by the administration of a therapeutically active amount of the pharmaceutical composition described in any one of the above embodiments. According to another embodiment, this invention allows for the formation of smaller deposits and greater precision in dosing because they are less concentrated and administered with finer needles, thus enabling the preparation of smaller and less viscous doses, for example, for lanreotide applications in ophthalmology, such as 20 mg or less or 0.1 mL or less, for patients suffering from glaucoma, macular edema, inflammation, diabetic retinopathy, or age-related macular degeneration. These characteristics are also suitable for applications of the product in dermatology, such as for the treatment of keloids. 20 The advantages of syringes and formulations according to this invention also allow for to perform these injections very quickly with a short piston stroke for these small volumes. According to the invention, these less viscous formulations with a lower lanreotide load also allow for more efficient preparation of combination compositions in which one or more other active ingredients are added to the lanreotide, which can also control their combined release for the same treatment. For example, in ophthalmology, a glucocorticoid such as dexamethasone, a monoclonal antibody, or a mixture of two or more of these active ingredients. The pharmaceutical composition as described above is prepared by a process comprising the following steps: 30 • preparation of the aqueous solvent comprising water and optionally ethanol and / or an amino acid, for example arginine, in a syringe • introduction of lanreotide into a suitable container, for example into a second syringe or into a syringe-shaped container, • connection of the 2 syringes or syringe-type containers with a 2-way connector, and hydration of the lanreotide with the aqueous solvent and homogenization of the composition by means of a mixing process at a temperature between 5 and 70 °C, preferably at room temperature. Furthermore, the entire preparation process can be controlled with respect to critical processing parameters such as temperature, pressure, number of cycles and syringe-valve diameter ratio, with equipment known to the person skilled in the art. According to another embodiment of the invention, the active ingredient can be pre-treated alone or with arginine in an aqueous medium in proportions and for varying durations, depending on the release control requirements. Lanreotide can, for example, be treated by lyophilization, drying, grinding, granulation, compaction, or sieving before the preparation of the pharmaceutical composition itself or in a pre-filled syringe according to the present invention. Any sterilization technique such as gamma irradiation, electron beam irradiation, steam or sterile filtration for a part of the process can be used to obtain a sterile pharmaceutical composition. According to another embodiment of the invention, the preparation of the pharmaceutical composition as such or present in a pre-filled syringe according to the present invention is carried out under aseptic conditions. 20 A pharmaceutical composition according to the present invention may be available under Pre-filled and ready-to-use presentation form. It may also be available as a ready-to-reconstitute presentation where a lyophilized product containing the active ingredient can be reconstituted extemporaneously with the aqueous solvent, and other additives if necessary as a solvent for reconstitution. As another embodiment, the pharmaceutical composition can be packaged in pre-filled syringes. The invention also relates to a kit comprising a prolonged and / or controlled-release pharmaceutical composition for parenteral administration, said composition comprising: 30 a) an aqueous solvent consisting of water and possibly an organic solvent miscible with water, preferably an alcohol, even more preferably ethanol b) lanreotide or a lanreotide salt, preferably lanreotide acetate, at a concentration of 11 to 25% by weight, preferably between 18 and 21% by weight relative to the total weight of the composition, c) optionally one or more amino acids, preferably arginine, d) optionally a pharmaceutically acceptable monomeric excipient, and a syringe having a needle with an external diameter equal to or less than 1.00 mm, an internal diameter equal to or less than 0.80 mm and a length preferably between 10 and 40 mm. Under the novel conditions of this invention, deposits are obtained by precipitation of lanreotide after interaction with the patient's tissues and bodily fluids at the injection site. This type of smaller, flatter deposit is better tolerated. Unexpectedly, lanreotide, used in more dilute forms than the semi-solid or paste-like formulations of current commercial compositions, can be combined in a presentation with an injection device featuring a needle finer than current needles, with an external diameter of at least 1.20 mm. Injection with this new presentation results in a different deposition, yielding controlled forms with novel and advantageous properties, useful for all the therapeutic needs of the product and capable of overcoming the limitations or problems posed by current controlled forms. According to another preferred embodiment, the invention relates to a pharmaceutical composition comprising: a) an aqueous solvent consisting of water and possibly an organic solvent miscible with water, preferably an alcohol, and even more preferably ethanol, b) lanreotide or a lanreotide salt, preferably lanreotide acetate, at a concentration of 11 to 25% by weight, preferably between 18 and 21% by weight relative to the total weight of the composition, c) possibly one or more amino acids, preferably arginine, d) possibly a pharmaceutically acceptable monomeric excipient, said composition being characterized in that, when administered by subcutaneous, normal or deep, or intramuscular injection into a patient using a syringe having an internal diameter of approximately 3.50 mm and equipped with a needle having an external diameter equal to or less than 1.00 mm and an internal diameter equal to or less than 0.80 mm and a length preferably between 10 and 40 mm, preferably a length of 20 to 30 mm, releases lanreotide or lanreotide salt over a period of at least 7 days, preferably at least 28 days. Animal studies were conducted to demonstrate that the deposits obtained, although different, maintained the controlled release or delayed effect of lanreotide. Depending on the objectives, it is possible to produce many different new products using the lanreotide compositions and the kits or pre-filled syringes available according to the invention. Without being exhaustive, the following are some examples of the different possibilities: -A lanreotide release profile similar to that of current commercial forms such as Somatuline® over 4 weeks with a composition containing 20% lanreotide in water and doses up to 120 mg in a 3.50 mm diameter syringe fitted with a 0.80 mm external diameter and 20 mm long needle for subcutaneous administration. -A higher lanreotide release profile than current forms such as 10 Somatuline® over 4 weeks with a composition containing 20% lanreotide in water and doses of 240mg or more in a 3.50 mm internal diameter syringe fitted with a 1.00 mm external diameter and 20 mm long needle for subcutaneous administration. -A higher lanreotide release profile than current forms such as Somatuline® over 2 weeks with a composition containing 20% lanreotide in water and doses up to 120mg in a 3.50 mm diameter syringe fitted with a 0.80 mm external diameter and 40 mm long needle for intramuscular administration. -A lanreotide release profile similar to that of current forms such as Somatuline® over 4 weeks with a composition containing 20% lanreotide in water and doses up to 100 mg in a 3.00 mm diameter syringe equipped with a 0.60 mm needle, 20 mm external diameter and 20 mm length for subcutaneous administration. -A release profile similar to that of current formulations such as Somatuline® over 4 weeks or more with a composition containing 20% in water and doses of 20mg or less in a syringe of 3.00 mm diameter or less fitted with a needle of 0.60 mm external diameter or less. -A higher lanreotide release profile than current forms such as Somatuline® over 2 weeks with a composition containing 20% lanreotide in water and doses up to 100 mg in a 3.00 mm diameter syringe fitted with a 0.70 mm external diameter and 30 mm long needle for intramuscular administration. -A lanreotide release profile similar to that of current forms such as 30 Somatuline® or higher than current forms over 4 or 2 weeks with compositions at 20% in water up to more than 120 mg in a standard pre-filled syringe classically to which a short subcutaneous or long intramuscular 21 or 20G luer-lock needle is attached. -A lanreotide release profile similar to or higher than that of current formulations such as Somatuline® over 4 or 2 weeks with a composition containing 20% lanreotide in a 5:95 alcohol / water mixture up to more than 120 mg in a standard syringe manufactured aseptically prepared extemporaneously stable at room temperature for subcutaneous or intramuscular administration. -A flatter lanreotide release profile than current forms such as Somatuline® over 4 or 8 weeks with a composition containing 25% lanreotide in a 25:75 alcohol / water mixture up to more than 120 mg in a standard syringe manufactured aseptically prepared extemporaneously stable at room temperature for subcutaneous or intramuscular administration. -A flatter lanreotide release profile than current formulations such as 10 Somatuline® over 2, 4, 8, or 12 weeks with a composition containing 20% lanreotide and 12% arginine in water up to more than 120 mg in a standard pre-filled syringe classically to which a short subcutaneous or long intramuscular luer-lock needle is attached. DESCRIPTION OF THE FIGURES Figure 1 represents comparable lanreotide acetate extrudates obtained after injection into air of a 19% and 25% by weight lanreotide composition contained in a 3.50 mm diameter syringe fitted with a 1.00 mm internal diameter needle. Figure 2 shows the evolution of the plasma concentration of lanreotide over time for the two compositions A and B prepared according to Example 13 Figure 3 shows the evolution of plasma lanreotide concentration as a function of time for the composition prepared according to Example 14 Figure 4 shows the evolution of the plasma concentration of lanreotide over time for the composition prepared according to Example 15 Figure 5 shows the evolution of the plasma concentration of lanreotide over time for the composition prepared according to Example 17 DETAILED DESCRIPTION OF THE INVENTION It is possible to describe the invention in more detail by specifying some examples of implementations according to this invention. 30 EXAMPLE 1 Preparation of compositions between 18 and 21% of lanreotide in the form of lanreotide acetate in two types of solvent, water and a 95:5% water / ethyl alcohol mixture The preparations are carried out using a back-and-forth technique between two syringe-type reservoirs, closed at one end by a piston and open at the other by a section connected to a valve. optionally allowing the lanreotide acetate powder to be conditioned under vacuum, to be hydrated with said solvents and to mix the product by back and forth by regulating the opening of the connection by the valve, this by optionally measuring the forces exerted to control the type of mixing to be carried out. Comparing the processes for preparing these mixtures to those for preparing a 25% lanreotide composition similar to the commercial product, it is clear that preparing these mixtures at concentrations between 18% and 21% is much easier and faster, and requires less mixing force. This also makes it possible to scale up this type of mixture to much larger volumes, or to prepare it using techniques other than those specifically designed for semi-solid or pasty mixtures. The mixing is simplified in such a way that it is also possible, according to protocols known to those skilled in the art, to fill syringes as is done with liquid forms, or to condition the required dose in each syringe in powder or lyophilized form so that it can then be hydrated extemporaneously and mixed manually at the time of use. This alternative presentation of lanreotide according to the invention allows, for example, the consideration of prolonged and / or controlled release compositions stable at room temperature or even compositions with variable concentrations from a single dose of lanreotide, to obtain profiles adapted to different therapeutic needs. 20 EXAMPLE 2 Composition with 19.0% lanreotide in water Batch prepared from 1.88 g of lanreotide acetate and purified water. The preparation is carried out using the back-and-forth technique described in Example 1, with two plastic syringes connected to a connector that allows mixing after hydration of the lanreotide acetate powder with water. The resulting composition is distributed through different injection systems to evaluate the injection force and other parameters such as peptide content and chromatographic purity. EXAMPLE 3 30 Composition with 19.5% lanreotide in water and ethyl alcohol Batch prepared from 0.36 g of lanreotide acetate and a 95:5 mixture of purified water and ethyl alcohol. The 95:5 water-alcohol mixture is prepared by mixing 1.906 g of purified water with 0.103 g of 96% ethyl alcohol. The preparation is carried out using the back-and-forth technique described in Example 1, with two plastic syringes connected to a connector that allows mixing after hydration of the lanreotide acetate powder with the water / ethyl alcohol mixture. The resulting composition is then distributed through different injection systems to evaluate the injection force and other parameters such as peptide content and chromatographic purity. EXAMPLE 4 Description of injection force measurements Injection force measurements of the compositions prepared as described in Example 1 are performed using a dynamometer (L1000R, Lloyd Instruments Ltd.) equipped with a calibrated force capture cell (NLC 100N, Lloyd Instruments Ltd.) coupled to a computer system for data acquisition and processing. For each measurement, the injection system (syringes and needles) containing the composition is placed on a support in a vertical position (needle downwards), and the dynamometer is used to move the plunger in the syringe to simulate an injection. The measurements are performed at a constant speed of 100 mm / min, and the force detected by the cell is recorded as a function of the plunger's displacement. The composition discharged during each test can be collected in a volumetric flask to complement physicochemical analyses, such as the peptide content of the samples described in Example 5. 20 EXAMPLE 5 Description of the process for determining peptide content and chromatographic purity The compositions prepared as described in Examples 1, 2, and 3 are analyzed by reverse-phase high-pressure liquid chromatography (RP-HPLC). For the determination of chromatographic purity, the area of the main peak corresponding to lanreotide is compared as a percentage to the total area of all detected peaks. For the determination of peptide content, the area of the main peak corresponding to lanreotide is used to calculate the concentration of the injected composition, taking into account the response areas obtained for injections of lanreotide reference standard compositions. From the concentration of the injected composition, the mass of the analyzed sample, and the volume of solution, the peptide content (mass percentage) of the composition can be calculated. Conditions and RP-HPLC method used by the inventors: - solvent for sample preparation: 0.1% acetic acid in HPLC quality water or an 85:15 mixture of acetic acid (0.1%) in HPLC quality water and acetonitrile. - column: C18 XBridge of 150 x 4.6 mm -Column temperature: 359C - Mobile phase A: 0.1% trifluoroacetic acid (TFA) in HPLC-grade water - Mobile phase B: 80:20 acetonitrile / HPLC-grade water mixture at 0.1% TFA - Flow rate: 0.9 mL / min - Elution: gradient of B in A (15% to 53.7% in 21.5 min then 70% at 22.5 min then 85.0% at 23.5 min) - Injection volume: between 10 and 100pL - Concentration of compositions: between 80 and 800 pg / mL of lanreotide - Detection: UV at 280 nm EXAMPLE 6 Packaging of the preparations in fine syringes of the type used for commercial insulin and in conventional pre-fillable syringes or reservoirs The inventors realized that filling syringes with the compositions prepared as described in Example 1 was simpler, faster, and less problematic than with a 25% equivalent mixture of the commercial product. The differences are so significant that it is also possible to fill syringe-type reservoirs in the traditional way, as with liquid injectables, and to use larger-diameter standard reservoirs, such as commercially available pre-filled cartridges or syringes, made of glass or plastic. For example, it is also possible to prepare pre-filled doses in standard glass syringes, such as HyPak™ syringes. EXAMPLE 7 Description of the distribution of a 19% composition in "fine" insulin-type syringes A batch prepared as described in Example 2, containing 19% lanreotide in water, is filled 30 times into thin, insulin-type plastic syringes with an internal diameter of 3.50 mm. The syringes are filled from the front by connecting the thin syringe to the end of one of the larger syringes used to prepare the composition. The charge of the composition moves the plunger of the thin syringe backward as it is inserted. For injected doses of 30 mg using a needle subsequently fitted with a diameter of 1.00 (OD) x 0.80 (ID) x 20 mm (L), 162 mg of the composition are loaded into each plastic syringe. The needle is then coupled to the syringe and protected by a standard cap. butyl. EXAMPLE 8 Description of the distribution of a 19% composition in commercially available pre-filled syringes A prepared batch, such as in Example 2, containing 19% lanreotide in water, is filled into 10 x 1.0 mL glass syringes. The glass syringes are filled from the rear, as in industrial filling, using a plastic cannula with an internal diameter of 3.50 mm and an external diameter smaller than the internal diameter of the glass syringes. For 30 mg injected doses using a subsequently attached 21G needle (16 or 25 mm in length), approximately 225 mg of the compound are loaded into the bottom of each glass syringe. A bromobutyl plunger is then positioned to minimize the volume of air trapped between the compound and the plunger. EXAMPLE 9 Example of injection force measurements 20. Injection force tests are carried out according to calibrated and validated protocols, as described. in Example 4. The maximum injection force expressed in newtons (N) is derived from data collected during discharge. In this example, representative needles of the commercial product Somatuline (1.20 mm external diameter) are compared with needles of smaller diameter, as well as the injection forces of compositions prepared according to examples 1, 2 and 3 through the same needles and different injection systems (syringe + needle). The results obtained are reported in the following table: % (w / w) lanreotide Solvent (water:alcohol) Injection System (in mm) Injection Force (Newtons) 25.0 100:0 Syringe Inner Diameter: 3.5 Needle (Dext / Dint / L): 1.2 / 1.0 / 20 14.3 19.0 100:0 Syringe Inner Diameter: 3.5 Needle (Dext / Dint / L): 1.2 / 1.0 / 20 5.5 18.7 100:0 Syringe inner diameter: 3.5 Needle (Dext / Dint / L): 1.0 / 0.8 / 20 8.8 18.8 100:0 Syringe inner diameter: 3.5 Needle (Dext / Dint / L): 0.8 / 0.6 / 20 11.9 25 75:25 Syringe inner diameter: 3.5 Needle (Dext / Dint / L): 1.0 / 0.8 / 10 7.3 19.9 90:10 Syringe inner diameter: 3.5 Needle (Dext / Dint / L): 1.2 / 1.0 / 20 7.3 19.5 95:5 Syringe inner diameter: 3.5 Needle (Dext / Dint / L): 1.2 / 1.0 / 20 8.3 By using more diluted compositions despite the choice of needles being much longer than those of commercial products limited to deep subcutaneous injections, it was observed under the conditions of the invention that injection forces were reduced by at least 3 or 4. EXAMPLE 10 Visual appearance and comparisons of extrudates obtained by injection through different needles To demonstrate the importance of large needle diameters according to known approaches, it can be verified that, prior to insertion, with needles of at least 1 mm lumen or internal diameter, commercial products containing 25% lanreotide with one of the more dilute compositions yield, after in-vitro injection, an extrude or cylinder of the same diameter. With finer needles combined with more dilute compositions, the inventors succeeded in obtaining, after in-vitro injection, a product that does not retain this shape, demonstrating the ability of this new presentation, with a finer needle and a more dilute composition, to not rely on deposition to control lanreotide release. Tests were conducted to evaluate the visual appearance and geometry of extrudates of 2 lanreotide compositions prepared as in Example 1, through different needles. The results are visible in Figure 1: 20 - On the left, an extrudate with a composition of 25% lanreotide, injected through a needle 1.00 mm internal diameter - In the middle, an extrudate with a composition of 19% lanreotide is injected through a needle with an internal diameter of 1.00 mm. - On the right, an extrudate with a composition of 19% lanreotide, injected through a needle with an internal diameter of 0.60 mm The results obtained with a needle with an internal diameter of 1.00 mm yielded similar extrudates. It was not possible to perform the same comparison with a 0.60 mm needle: only the 19% lanreotide composition could be manually extruded, and the resulting extrudate was significantly different. EXAMPLE 11 Manual injection 10 For doses of compositions prepared according to Example 2 at 19% lanreotide pre Using 1.00 mL standard glass syringes, it was possible to verify that manual injection can be performed using a standard 21G, 25 mm hypodermic needle. These manual injections were performed using standard finger rests available for standard commercial syringes. The tests are carried out using standard needles attached extemporaneously to the different syringes allowing for normal or deep subcutaneous injections depending on the length of the needle varying from 10 to 20mm as well as intramuscular injections with long needles of 25 to 40mm. The combination of the advantages of needle implantation and product administration with 20 less force, choice of injection site, less viscous deposit which retains its shape less or diffuses more and reduction of volume by precipitation of lanreotide are all factors which contribute to making these treatments easier, more comfortable, less painful to administer and better tolerated at the deposition site by avoiding sensitive nodules. EXAMPLE 12 Stability study of 20% lanreotide compositions in water and in a water-ethanol mixture. A 25% lanreotide composition prepared as described in Example 1 with a mixture of purified water and 75:25 ethyl alcohol was tested for stability at 59°C and 259°C / 60% RH. After 1 month of storage under these conditions, the peptide purity was determined by RP-HPLC is compared to the initial purity. The results are reported in the following table. Purity at t=0 Purity at t=1 month and storage at 59°C Purity at t=1 month and storage at 259°C / 60%RH 99% Ar 99% Ar 98.9% Ar The stability of different compositions was studied according to protocols designed to predict the feasibility of ready-to-use presentations under various manufacturing conditions, both aseptic and with terminal sterilization. Compositions containing 20% lanreotide were shown to be stable. Unexpectedly, considering other data with a low percentage of organic solvent, it was found that compositions with a water mixture containing 10% or less ethanol were also stable. It is therefore possible with these 2 types of delayed and / or controlled release compositions 10 less viscous to offer a presentation of ready-to-use injectable product without product reconstitution steps before injection. EXAMPLE 13 Pharmacokinetic (PK) profiles obtained in rats To verify the functioning and feasibility of new injectable products from these new presentations, pharmacokinetic studies were carried out on rats and dogs. The following two compositions, prepared according to Example 1 using lanreotide acetate, were tested on rats: 20 - Formulation A: 24.6% lanreotide in a mixture of purified water and ethyl alcohol 75:25 - Formulation B: 27.9% lanreotide in purified water. Doses of approximately 15 mg are injected subcutaneously, and blood samples are collected throughout the study. The various plasma samples derived from the blood samples are analyzed by LC-MS to determine the plasma concentration of lanreotide. The results are visible in Figure 2, which shows the evolution of the plasma concentration of lanreotide as a function of time for the two compositions A and B. In both cases, a prolonged release of lanreotide is observed. However, it is clearly visible that composition A, although containing a lower percentage of 30 lanreotide, provides an improved release profile: the initial burst or Cmax is reduced, which allows lanreotide levels to almost double at 4 weeks. It is possible to test this new presentation with, for example, a 1.00 mm diameter needle and a 20% lanreotide composition and compare it with known references of a commercial 25% composition injected with a 1.20 mm diameter needle. The results obtained in this example suggest that it is possible to achieve comparable, or even better controlled, release profiles with a new presentation according to the invention, thanks to the arrangement of the depot in its precipitation mode. It is therefore possible to estimate that this type of new presentation, with appropriate needles, could allow, for example, subcutaneous administration every 28 days in the case of acromegaly, with a release profile exhibiting less burst and a higher level at the end of the interval; or, for example, intramuscular administration every 14 days with a consistently higher release profile followed by a rapid decrease in lanreotide levels for the treatment of neuroendocrine tumors. To verify the functionality of the new controlled formulations, it is also possible to test this new presentation under extreme conditions of significantly lower viscosity, for example, using a 20% lanreotide preparation in a 95:5% water-alcohol mixture. In this case, it is possible to demonstrate that the release is maintained at these limits and that it is also possible to obtain new, more advantageous profiles, such as the ability to achieve higher release levels, better suited and necessary for certain treatments, as in the case of NETs. 20 EXAMPLE 14 Example of pharmacokinetic (PK) profile obtained on dogs In general, presentations according to the invention are likely to give profiles with higher administered doses on dogs than on rats, thus easier to compare to doses used in humans in clinical settings. A batch prepared according to Example 1 from lanreotide acetate in purified water is tested in dogs at a lanreotide concentration of 20.2%. Doses of 60 mg (lanreotide) are injected intramuscularly, and blood samples are collected throughout the study. The doses are packaged in 3.0 mm diameter syringes coupled with 30 needles measuring 0.8 x 0.6 x 19 mm. Intramuscular administration with these small-diameter needles is easily performed. The different plasma samples derived from the blood samples are analyzed by LC-MS to determine the plasma concentration of lanreotide. Prolonged lanreotide release is observed over a period of at least 1 month. The results are shown in Figure 3, which plots the evolution of plasma lanreotide concentration over time. EXAMPLE 15 Pharmacokinetic (PK) profile obtained in dogs A formulation prepared according to Example 1 from lanreotide acetate and a 93:7% purified water / ethyl alcohol mixture was tested on dogs at a lanreotide concentration of 20.7%. Doses of 60 mg of lanreotide were injected intramuscularly, and 10 blood samples were collected throughout the study. The various plasma samples derived from the blood samples were analyzed by LC-MS to determine the plasma concentration of lanreotide. The results are visible in Figure 4, which shows the evolution of the plasma concentration of lanreotide over time. Prolonged lanreotide release is observed for a period of at least 1 month. EXAMPLE 16 Preparation of an aqueous lanreotide composition with arginine and analytical purity results 20 A new composition is obtained from 0.40 g of lanreotide acetate and a L-arginine solution, at 0.072 g / g in purified water. The composition is obtained by mixing lanreotide acetate with 2.67 g of arginine solution. The two components are weighed into 5 mL plastic syringes. The mixing is carried out by a back-and-forth movement between the two syringes connected by a connector as described in Example 1. At the end of the mixing phase, the composition is dispensed into 1.0 mL plastic syringes (approximately 530 mg of composition per syringe). This composition can be injected as is or can be lyophilized to obtain a form ready for reconstitution before injection. RP-HPLC analyses performed on the products as described in Example 5 indicate that the purity of the peptide is maintained above 95% (98.6%). EXAMPLE 17 Pharmacokinetic (PK) profile obtained in rats with an arginine-containing composition A solid composition of lanreotide acetate with L-arginine is tested on rats. The composition is prepared from an 11% aqueous composition of lanreotide to obtain a final lanreotide content of 57.9% w / w with approximately 0.57 g of arginine per g of lanreotide. Doses of approximately 3.5 mg are injected subcutaneously, and blood samples are collected throughout the study. The various plasma samples derived from the blood samples are analyzed by LC-MS to determine the plasma concentration of lanreotide. The results are shown in Figure 5, which plots the evolution of plasma lanreotide concentration over time. A prolonged release of lanreotide 10 was observed for a period of at least 4 weeks. Compared to the equivalent arginine-free formulations, this showed an improved pharmacokinetic profile. EXAMPLE 18 Determination of the shape of deposits by palpation and by extemporaneous sampling of different compositions injected subcutaneously in rabbits: results and possible extrapolations Solutions at different concentrations are prepared as described in Example 1. Formulation A: 20% lanreotide formulation in water Formulation B: 20% lanreotide formulation in a 95:5% water / ethanol mixture 20 - Reference Formulation: a 25% lanreotide-in-water formulation that replicates the conditions of current commercial products. These formulations are injected into the rabbit according to the following model: A first arm is injected at t=0 with 30mg of Formulation A and 30mg of Reference Formulation at two different injection sites; at t=7 days with 30mg of Formulation A at a third injection site, and at t=11 days with 30mg of Formulation A at a fourth injection site, i.e. 4 injections performed in total; A second arm is injected at t=0 with 30 mg of Formulation B and 30 mg of Reference Formulation at two different injection sites; at t=7 days with 30 mg of Formulation B at a third injection site; and at t=11 days with 30 mg of Formulation B at a third injection site. fourth injection site, making a total of 4 injections performed; It is possible to feel the different deposits through the skin to follow the evolution of their shape and consistency, and after two weeks to verify their nature by extemporaneous sampling. It is noted that for these same low doses of 30mg of injected lanreotide, the deposits prepared from Formulation Reference, although of smaller volume, are more sensitive or palpable than those from Formulations A or B. The less viscous deposits made from the water-alcohol mixture of Formulation B are the least palpable. Two weeks after the animals were sacrificed, all 20% Formulation A or Formulation B deposits, after 3, 7, or 14 days, showed a white mass of varying solidity corresponding to lanreotide precipitation. The lanreotide content of these deposits was analyzed, and it was found that the remaining amounts of this peptide were inversely proportional to the time after injection and comparable at two weeks to those obtained with the Reference Formulation deposit. This demonstrates the possibility of obtaining, with these new presentations which combine finer needles and more diluted compositions, controlled compositions of lanreotide over a week and longer according to a different release process.
Claims
Claims 1. Set consisting of a syringe pre-filled with a pharmaceutical composition characterized in that: a) the pre-filled syringe has a diameter greater than 3.00 mm, preferably 3.50 mm in diameter, and is equipped with a needle having an external diameter equal to or less than 1.00 mm and an internal diameter equal to or less than 0.80 mm and a length preferably between 10 and 40 mm, preferably a length of 20 to 30 mm, 10 b) the pharmaceutical composition comprises: 1) an aqueous solvent consisting of water and optionally a water-miscible organic solvent, preferably an alcohol, even more preferably ethanol, 2) lanreotide or one of its salts, preferably lanreotide acetate at a concentration ranging from 11 to 25% by weight of lanreotide, preferably between 18 and 21% by weight of lanreotide relative to the total weight of the composition, 3) optionally one or more amino acids, preferably arginine, 4) optionally a monomeric excipient accepted by the pharmacopoeia, said pharmaceutical composition being contained in said syringe. 20 2. Assembly according to claim 1, characterized in that said composition is under a form suitable for parenteral administration by subcutaneous, normal or deep injection, or intramuscular injection in a patient of said composition using said syringe releasing lanreotide or lanreotide salt over a period of at least? days, 7 to 14 days, 14 to 28 days, preferably at least 28 days.
3. Assembly according to claim 1, characterized in that said composition comprises ethanol in a proportion preferably between 3% and 23%, preferably from 3 to 10% by weight relative to the total weight of the composition. 30 4. Assembly according to one of claims 1 to 3, characterized in that said composition comprises an amino acid, preferably arginine, at a concentration ranging from 0.1 to 13% by weight relative to the total weight of the composition.
5. Assembly according to one of claims 1 to 4 characterized in that said syringe is a manual syringe with a piston rod provided with a standard needle of the luer-lock type having an external diameter of 0.80 to 1.00 mm, an internal diameter of 0.60 to 0.80 mm and a length of 20 to 30 mm.
6. Assembly according to one of claims 1 to 5 characterized in that said syringe comprises a piston rod provided with a standard needle of the luer-lock type having an external diameter of 0.80 to 1.00 mm, an internal diameter of 0.60 to 0.80 mm and a length of approximately 20 mm, and is pre-filled with a prolonged-release pharmaceutical composition for parenteral administration, said composition comprising an aqueous solvent consisting of water and optionally 3% ethyl alcohol, lanreotide acetate in an amount sufficient for the lanreotide concentration to be approximately 18% to 21% by weight relative to the total weight of the composition, and arginine at a concentration ranging from 0.1 to 13% by weight relative to the total weight of the composition.
7. Assembly according to one of claims 1 to 6 characterized in that said syringe comprises a piston rod provided with a standard needle of the luer-lock type having an external diameter of approximately 0.80 mm, an internal diameter of approximately 0.60 mm and a length of approximately 20 mm, and is pre-filled with a prolonged-release pharmaceutical composition for parenteral administration, said composition comprising water and lanreotide acetate in an amount sufficient for the concentration of lanreotide to be approximately 20% by weight relative to the water.
8. Pharmaceutical composition comprising: 1) an aqueous solvent consisting of water and optionally a water-miscible organic solvent, preferably an alcohol, even more preferably ethanol, 2) lanreotide or one of its salts, preferably lanreotide acetate at a concentration ranging from 11 to 25% by weight of lanreotide, preferably between 18 and 21% by weight of lanreotide relative to the total weight of the composition, 30 3) optionally one or more amino acids, preferably arginine, 4) optionally a monomeric excipient accepted by the pharmacopoeia, for its use in the treatment of acromegaly or neuroendocrine tumors, in dermatology or in ophthalmology when said pharmaceutical composition is contained in a syringe pre-filled with said pharmaceutical composition, said syringe being characterized in that it has a diameter greater than 3.00 mm, preferably 3.50 mm in diameter, and is equipped with a needle having an external diameter equal to or less than 1.00 mm and an internal diameter equal to or less than 0.80 mm and a length preferably between 10 and 40 mm, preferably a length of 20 to 30 mm.
